Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM

Irinotecan has radiosensitizing effects and shows synergism with nitrosoureas. We performed a Phase II study of RT and irinotecan, followed by BCNU plus irinotecan in newly-diagnosed GBM. The MTD for patients receiving enzyme-inducing anticonvulsants (EIAC) was as follows: irinotecan 400 mg/m(2)/wee...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jaeckle, Kurt A., Ballman, Karla V., Giannini, Caterina, Schomberg, Paula J., Ames, Matthew M., Reid, Joel M., McGovern, Renee M., Safgren, Stephanie L., Galanis, Evanthia, Uhm, Joon H., Brown, Paul D., Hammack, Julie E., Arusell, Robert, Nikcevich, Daniel A., Morton, Roscoe F., Wender, Donald B., Buckner, Jan C.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2897141/
https://ncbi.nlm.nih.gov/pubmed/20063115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-009-0103-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars